Biblio Discovery — Demo Discovery Service

4 hasil untuk "Samad, Muhammad Ammar"

Menampilkan 1–4 · 0,28 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Chronic myeloid leukemia: a type of MPN

    Samad, Muhammad Ammar; Mahboob, Eman; Mansoor, Hussain

    Blood Res · 2022 · Inggris · PubMed Central

    This review article classifies chronic myeloid leukemia (CML) based on cytogenetic analyses and different mutations detected in CML patients. The use of advanced technologies, such as karyotyping, fluorescent in situ hybridization, and comparative genomic hybridization, has allowed us to study CML…

  2. Artikel Jurnal Teks lengkap

    The dual role of empagliflozin: Cardio renal protection in T2DM patients

    Shafiq, Aimen; Mahboob, Eman; Samad, Muhammad Ammar dkk.

    Ann Med Surg (Lond) · 2022 · Inggris · PubMed Central

    Empagliflozin (Jardiance®) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective…

  3. Artikel Jurnal Teks lengkap

    Types of T-cell lymphoma-a cytogenetic perspective

    Samad, Muhammad Ammar; Mahboob, Eman; Shafiq, Aimen dkk.

    Ann Med Surg (Lond) · 2022 · Inggris · PubMed Central

    T cell lymphoma, a type of non-Hodgkin lymphomas is a rare form of malignancy with poor outcomes. TCLS are a heterogeneous group of lymphoid malignancies that occur in nodal and extranodal sites. There are two main types of TCLs namely T-lymphoblastic lymphoma/leukemia and Peripheral T-cell…

  4. Artikel Jurnal Teks lengkap

    Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis()

    Ansari, Huzaifa Ul Haq; Samad, Muhammad Ammar; Mahboob, Eman dkk.

    Am J Prev Cardiol · 2024 · Inggris · PubMed Central

    BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI…